IEHP UM Subcommittee Approved Authorization Guidelines

Intravenous Immunoglobulin (IVIG) for Multiple Sclerosis

Policy:
On August 28, 2008, the IEHP Utilization Management Subcommittee discussed the use of Intravenous Immunoglobulin (IVIG) for Multiple Sclerosis (MS). Based on this review, the IEHP UM Subcommittee adopted NICE’S recommendation for IVIG for Multiple Sclerosis as a covered benefit.

National Institute for Clinical Excellence (NICE, 2004):
The National Institute for Clinical Excellence (NICE) guideline recommendations from 2004, states that IVIG for managing relapsing-remitting MS (RRMS) and secondary progressive MS should only be used in specific circumstances:

1. After full discussion and consideration of all risks;
2. With formal evaluation, preferably in a randomized or other prospective study; and
3. By an expert in the use of medicines in MS with close monitoring for adverse events.

Effective Date: August 28, 2008
Reviewed Annually: November 9, 2016

Revised:

Bibliography:
ECRI Institute Custom Hotline Response: Intravenous Immunoglobulin (IVIG) for Multiple Sclerosis, June 2008.
Disclaimer
IEHP Clinical Authorization Guidelines (CAG) are developed to assist in administering plan benefits, they do not constitute a description of plan benefits. The Clinical Authorization Guidelines (CAG) express IEHP's determination of whether certain services or supplies are medically necessary, experimental and investigational, or cosmetic. IEHP has reached these conclusions based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). IEHP makes no representations and accepts no liability with respect to the content of any external information cited or relied upon in the Clinical Authorization Guidelines (CAG). IEHP expressly and solely reserves the right to revise the Clinical Authorization Guidelines (CAG), as clinical information changes.